SM
TVRD

Senvest Management’s Tvardi Therapeutics TVRD Stock Holding History

Senvest Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-808
Closed -$292K – 91
2015
Q1 		$292K Sell
808
-239
-23% -$90.4K 0.02% 89
2014
Q4 		$376K Buy
+1,047
New +$337K 0.03% 73

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Senvest Management's TVRD Position: Q2 2015 in Review

Senvest Management sold out of Tvardi Therapeutics (TVRD) in Q2 2015, closing a stake of 808 shares — an estimated $292K sold.

Senvest Management first reported a position in TVRD in Q4 2014 and held it in 2 quarters. The position peaked at $376K in Q4 2014. 75 funds tracked by Wall St. Rank hold TVRD as of Q2 2015.

  • Senvest Management reported no remaining Tvardi Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Senvest Management sold 808 Tvardi Therapeutics shares in Q2 2015, an estimated $292K.
  • Senvest Management first reported a position in Tvardi Therapeutics in Q4 2014 and held it in 2 quarters.
  • Senvest Management's Tvardi Therapeutics position peaked at $376K in Q4 2014.
  • 75 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2015.

Based on Senvest Management's 13F filing for Q2 2015, filed 14 Aug 2015.